This company has been acquired
AGRX Stock Overview
A women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Agile Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.51 |
| 52 Week High | US$2.63 |
| 52 Week Low | US$0.20 |
| Beta | 1.58 |
| 1 Month Change | 4.14% |
| 3 Month Change | 293.23% |
| 1 Year Change | -27.05% |
| 3 Year Change | -99.94% |
| 5 Year Change | -99.93% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Agile appoints chief commercial officer from within ranks amid leadership revamp
Oct 10Agile gains as H.C. Wainwright sees 630% upside potential
Jul 11Agile Therapeutics prices $24M upsized stock offering
Jul 01Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy
Apr 04Agile Therapeutics: Bullish On Capitulation And Max Pain
Oct 19Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy
Jul 30Agile Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 06How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?
Feb 25
Agile Therapeutics issues cash projection at JP Morgan healthcare conference
Jan 14Assessing Agile Therapeutics
Jan 10How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?
Jan 04Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch
Nov 30Agile Therapeutics EPS in-line
Nov 12Shareholder Returns
| AGRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.4% | -0.6% | -0.2% |
| 1Y | -27.1% | 3.0% | 25.8% |
Return vs Industry: AGRX underperformed the US Pharmaceuticals industry which returned 19% over the past year.
Return vs Market: AGRX underperformed the US Market which returned 25.9% over the past year.
Price Volatility
| AGRX volatility | |
|---|---|
| AGRX Average Weekly Movement | 93.4% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AGRX's share price has been volatile over the past 3 months.
Volatility Over Time: AGRX's weekly volatility has increased from 49% to 93% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 19 | Al Altomari | www.agiletherapeutics.com |
Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Agile Therapeutics, Inc. Fundamentals Summary
| AGRX fundamental statistics | |
|---|---|
| Market cap | US$10.43m |
| Earnings (TTM) | -US$15.86m |
| Revenue (TTM) | US$21.57m |
0.5x
P/S Ratio-0.7x
P/E RatioIs AGRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGRX income statement (TTM) | |
|---|---|
| Revenue | US$21.57m |
| Cost of Revenue | US$7.84m |
| Gross Profit | US$13.73m |
| Other Expenses | US$29.58m |
| Earnings | -US$15.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.30 |
| Gross Margin | 63.63% |
| Net Profit Margin | -73.52% |
| Debt/Equity Ratio | 0% |
How did AGRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/26 07:14 |
| End of Day Share Price | 2024/08/26 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Agile Therapeutics, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chiara Russo | Cantor Fitzgerald & Co. |
| Colin Scarola | CFRA Equity Research |
| Edward White | FBR Capital Markets & Co. |